![Figure 6: LP-284 is selectively lethal in cells with TC-NER deficiency. non-Hodgkin's lymphoma](https://www.oncotarget.net/wp-content/uploads/2023/06/Screen-Shot-2023-06-12-at-4.04.43-PM-300x182.png)
LP-284 Targets Non-Hodgkin’s Lymphoma and DNA Damage Repair Deficiency
June 12, 2023
we demonstrated the new acylfulvene compound LP-284 has anti-tumor activity including nanomolar potency in fifteen in vitro NHL cell lines and in vivo preclinical NHL models.ā€¯BUFFALO, NY- June 12,... read more